RIP/Rab Inhibitors
RIP/Rab inhibitors belong to a distinct chemical class of compounds that exert their effects by selectively targeting and inhibiting the activity of RIP (Receptor-Interacting Protein) and Rab (Ras-related proteins in brain). These inhibitors have garnered significant attention in the field of molecular biology and pharmacology due to their ability to modulate key cellular processes through the regulation of RIP and Rab signaling pathways. RIP proteins are known to play a vital role in the regulation of cell death and inflammation, while Rab proteins are essential for intracellular vesicle trafficking, maintaining organelle integrity, and directing cellular transport.
By specifically targeting these crucial proteins, RIP/Rab inhibitors offer researchers a valuable tool to dissect the intricate molecular mechanisms underlying cell signaling and intracellular transport. This class of inhibitors is characterized by their diverse chemical structures and unique binding interactions with RIP and Rab proteins, which allows for the design of highly specific and potent compounds. Ongoing research endeavors continue to explore the full potential and scope of these inhibitors in uncovering new insights into cellular biology and potentially identifying novel avenues in the future.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A potent kinase inhibitor known to nonspecifically inhibit a wide range of protein kinases which could affect RIP kinase activity. | ||||||
YM 254890 | 568580-02-9 | sc-507356 | 1 mg | $510.00 | ||
A GTPase inhibitor that could potentially inhibit the function of Rab GTPases by preventing GTP binding. | ||||||
CCG-1423 | 285986-88-1 | sc-205241 sc-205241A | 1 mg 5 mg | $30.00 $90.00 | 8 | |
Could inhibit RhoA signaling, which is often upstream of various kinases and Rab GTPases in cellular pathways. | ||||||
2-(Benzoylcarbamothioylamino)-5,5-dimethyl-4,7-dihydrothieno[2,3-c]pyran-3-carboxylic Acid | 314042-01-8 | sc-503400 | 10 mg | $300.00 | ||
A multi-kinase inhibitor that may affect RIP kinases among other targets, potentially reducing their expression. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $151.00 $609.00 | 75 | |
Disrupts Rac1 interaction with its guanine nucleotide exchange factors, potentially impacting Rab protein localization and function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
Inhibits MEK, which could indirectly affect RIP kinase signaling pathways and expression levels. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $137.00 $512.00 | 7 | |
A selective inhibitor of Cdc42 GTPase, which may interact with Rab GTPases, potentially modifying their expression. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that could affect a wide range of signaling pathways, possibly including those involving RIP kinases. | ||||||
Tozasertib | 639089-54-6 | sc-358750 sc-358750A | 25 mg 50 mg | $62.00 $87.00 | 4 | |
Inhibits Aurora kinases and could affect cell cycle progression, thereby potentially reducing the expression of many proteins, including RIPs. | ||||||
ZCL278 | 587841-73-4 | sc-507369 | 10 mg | $115.00 | ||
A Cdc42 GTPase inhibitor that could interfere with Rab GTPase signaling indirectly by modulating cytoskeletal dynamics. | ||||||